Drugs / Wilfactin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02488525 | Jan 2016 → Sep 2018 | heart failure | University Hospital, Lille | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-06-06 | Groupe Lfb | Regulatory LFB announces the extension of the indications of WILFACTIN® / WILLFACT® to the entire paediatric population in the European Union groupe-lfb.com ↗
LFB announced today the extension of the indications of WILFACTIN® / WILLFACT® to the entire paediatric population of the European Union and United Kingdom. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-06-06 | Groupe Lfb | LFB announces the extension of the indications of WILFACTIN® / WILLFACT® to the entire paediatric population in the European Union groupe-lfb.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Wilfactin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02488525 ↗ |
| Modality | Protein / enzyme biologic | “Prophylactic treatment with VWF factor concentrate” NCT02488525 ↗ |